Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is This Biotech Stock a Bad News Buy?

TheMotleyFool

0 0

Is This Biotech Stock a Bad News Buy?: https://g.foolcdn.com/editorial/images/687856/gettyimages-1315315110.jpg

Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm.

But even though Biogen's stock is on sale, that doesn't necessarily make its shares a buy. Right now, the company's prospects still look dim. Let's look into what's going on with this biotech giant.